Literature DB >> 10730737

Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.

L P Perrault1, A Y Denault, M Carrier, R Cartier, S Bélisle.   

Abstract

PURPOSE: Postoperative delirium occurs in about 2% of patients undergoing major cardiac surgery including coronary artery bypass grafting surgery (CABG). Haloperidol (Sabex, Boucherville, Canada) is a drug commonly used in the intensive care unit for the treatment of delirium and is usually considered safe even at high doses and is rarely implicated in the development of malignant ventricular arrhythmias such as torsades de pointes. The purpose of this study is to report such a complication of use of haloperidol after myocardial revascularization. CLINICAL FEATURES: The patient reported underwent uneventful triple bypass surgery. Administration of large intravenous doses of haloperidol was necessary for control of psychomotor agitation due to delirium. Torsades de pointes occurred in the absence of QT prolongation on the third postoperative day following use of the drug with no other obvious etiological factor.
CONCLUSION: Awareness of this rare complication is key to judicious use of this drug in the post CABG patient in whom such an arrhythmia may have very deleterious consequences because of the underlying cardiac condition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10730737     DOI: 10.1007/BF03018922

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  13 in total

Review 1.  Clinical pharmacology of old age syndromes.

Authors:  C Broadhurst; K C M Wilson; M T Kinirons; A Wagg; J K Dhesi
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 2.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

Review 3.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Delirium and cognitive dysfunction in the intensive care unit.

Authors:  Russell R Miller; E Wesley Ely
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 5.285

5.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

6.  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Authors:  Andrew J Muzyk; Amber Rayfield; Jane Y Revollo; Heather Heinz; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

7.  Drug-specific risk of severe QT prolongation following acute drug overdose.

Authors:  Sharan L Campleman; Jeffery Brent; Anthony F Pizon; Joshua Shulman; Paul Wax; Alex F Manini
Journal:  Clin Toxicol (Phila)       Date:  2020-04-07       Impact factor: 4.467

Review 8.  Perioperative torsade de pointes: a systematic review of published case reports.

Authors:  Joshua Johnston; Swatilika Pal; Peter Nagele
Journal:  Anesth Analg       Date:  2013-06-06       Impact factor: 5.108

9.  Olanzapine vs haloperidol: treating delirium in a critical care setting.

Authors:  Yoanna K Skrobik; Nicolas Bergeron; Marc Dumont; Stewart B Gottfried
Journal:  Intensive Care Med       Date:  2003-12-19       Impact factor: 17.440

10.  Haloperidol prophylaxis in critically ill patients with a high risk for delirium.

Authors:  Mark van den Boogaard; Lisette Schoonhoven; Theo van Achterberg; Johannes G van der Hoeven; Peter Pickkers
Journal:  Crit Care       Date:  2013-01-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.